company background image
AXGN logo

Axogen NasdaqCM:AXGN Stock Report

Last Price

US$14.85

Market Cap

US$631.1m

7D

3.1%

1Y

107.7%

Updated

19 Dec, 2024

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Axogen, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Axogen
Historical stock prices
Current Share PriceUS$14.85
52 Week HighUS$15.90
52 Week LowUS$5.55
Beta1.06
1 Month Change16.47%
3 Month Change5.47%
1 Year Change107.69%
3 Year Change51.22%
5 Year Change-18.54%
Change since IPO447.97%

Recent News & Updates

Recent updates

Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Sep 14
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Aug 20
Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Jul 29
A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Jun 12
Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Apr 16
Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Mar 28
Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Jan 26
Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Sep 10
We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

Aug 09
Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

Jan 13
AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

Is AxoGen (NASDAQ:AXGN) A Risky Investment?

Sep 10
Is AxoGen (NASDAQ:AXGN) A Risky Investment?

AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings

Aug 02

Shareholder Returns

AXGNUS Medical EquipmentUS Market
7D3.1%-3.6%-4.0%
1Y107.7%11.2%24.0%

Return vs Industry: AXGN exceeded the US Medical Equipment industry which returned 11.2% over the past year.

Return vs Market: AXGN exceeded the US Market which returned 24% over the past year.

Price Volatility

Is AXGN's price volatile compared to industry and market?
AXGN volatility
AXGN Average Weekly Movement7.9%
Medical Equipment Industry Average Movement7.8%
Market Average Movement6.4%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: AXGN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: AXGN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a427n/awww.axogeninc.com

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.

Axogen, Inc. Fundamentals Summary

How do Axogen's earnings and revenue compare to its market cap?
AXGN fundamental statistics
Market capUS$631.08m
Earnings (TTM)-US$14.31m
Revenue (TTM)US$180.86m

3.6x

P/S Ratio

-45.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AXGN income statement (TTM)
RevenueUS$180.86m
Cost of RevenueUS$38.43m
Gross ProfitUS$142.43m
Other ExpensesUS$156.74m
Earnings-US$14.31m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin78.75%
Net Profit Margin-7.91%
Debt/Equity Ratio50.0%

How did AXGN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 22:49
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Axogen, Inc. is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
William PlovanicCanaccord Genuity
Caitlin CroninCanaccord Genuity